Valganciclovir 1 CMV valganciclovir VGCV CMV IgM CMV-DNA CMV 34 VGCV 2 1 CMV CMV ganciclovir valganciclovir MRI cytomegaloviru

Size: px
Start display at page:

Download "Valganciclovir 1 CMV valganciclovir VGCV CMV IgM CMV-DNA CMV 34 VGCV 2 1 CMV CMV ganciclovir valganciclovir MRI cytomegaloviru"

Transcription

1 Valganciclovir 1 CMVvalganciclovirVGCV CMV IgM CMV-DNA CMV 34 VGCV 2 1 CMV CMV ganciclovirvalganciclovir MRI cytomegalovirus; CMV TORCH CMV 1 CMV valganciclovirvgcv ,856 gappropriate for dates; AFD 48 cm 35 cm 5 refer 11 auditory brain response; ABRauditory steady-state response; ASSR MRI * 1ab cm0.95sd 3,280 g0.70sd 35 cm1.21sd MRI CMV-DNA PCR CMV CMV-DNA 1 ganciclovirgcvvgcv VGCV VGCV 16 mg/kg2 1 CMV CMV 1 2 CMV 6 55

2 A B a C D E b F G H c 1 MRI a 11 ABFLAIR TI:2300 msectr:8320 msecte:90 msec b 3 VGCV1 CDFLAIR TI:2500 msectr:9000 msecte:137 msec ET1 TR:494 msecte:12 msec c 11 VGCV2 FGFLAIR TI:2300 msectr:9000 msecte:137 msec HT1 TR:562 msecte:12 msec * T2 * VGCV :valganciclovir 1 W 21 WBC /l Neut 19.3 % Lymph 68.1 % RBC 373 /l Hb 11.7 g/dl Plt 29.3 /l 21 AST 35 U/l ALT 21 U/l LD 305 U/l T-BIL 0.54 mg/dl BUN 0.54 mg/dl Cre 0.20 mg/dl Na 139 meq/l Cl 105 meq/l K 5.9 meq/l CRP 0.3 mg/dl 21 CMV-IgM Toxoplasma IgG CMV-DNA CMV-DNA 33 Glu 34 mg/dl Cl 119 meq/l TP 85 mg/dl 18 /l CMV-DNA 56

3 copies/ml 100,000,000,000 VGCV ,000,000,000 VGCV ,000,000,000 C M V 100,000,000 10,000,000 1,000, ,000 10,000 1, CMV CMV CMV-DNA 1 500copies/mL CMV :cytomegalovirusvgcv:valganciclovir CMV 500copies/mL CMV-DNA MRI * 3 4 CT 11 MRI T2 FLAIR CMV 1ch MRI ABR 3 CMV % 10% 10 15% CMV % 20% 1,000 1 CMV % % CMV 5 CMV CMV 30 Guthrie DNA CMV 2003 Kimberlin CMV GCV GCV VGCV GCV VGCV CMV 89 evidence 34 VGCV GCV 57

4 a b c 0.1V 0.2V 0.2V ms ms ms a 32 b 5 VGCV2 c V 0.5V 0.2V dB 70dB 60dB ms dB 60dB 50dB ms 3 ADL VGCV VGCV CMV VGCV GCVVGCV ;32 : CMV http ://mhlw-grants.niph.go.jp/niph/ search/nisr00.do ;50 : Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 2002 ;15 : Cheeran MC, Lokensgard JR, Schleiss MR. Neuropathogenesis of congenital cytomegalovirus infection :disease mechanisms and prospects for intervention. Clin Microbiol Rev 2009 ;22 : Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system :a randomized, controlled trial. J Pediatr 2003 ;143 : Kimberlin DW, Acosta EP, Sanchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008 ;197 : Schulzke S, Buhrer C. Valganciclovir for treatment of congenital cytomegalovirus infection. Eur J Pediatr 2006 ;165 : Lombardi G, Garofoli F, Villani P, et al. Oral valganciclovir treat- 58

5 ment in newborns with symptomatic congenital cytomegalovirus infection. Eur J Clin Microbiol Infect Dis 2009 ;28 : Kashiwagi Y, Kawashima H, Nakajima J, et al. Efficacy of prolonged valganciclovir therapy for congenital cytomegalovirus infection. J Infect Chemother 2011 ;17 : Successful Treatment of Congenital Cytomegalovirus Infection with Valganciclovir Yu Ishida, MD, Tasuku Miyajima, MD, Masaru Shimura, MD, Shinichiro Morichi, MD, Yasuyuki Morishima, MD, Hiroaki Ioi, MD, Shingo Oana, MD, Gaku Yamanaka, MD, Hisashi Kawashima, MD and Akinori Hoshika, MD Department of Pediatrics, Tokyo Medical University, Tokyo Congenital cytomegaloviruscmvinfection occurs frequently in neonates. However, there are no screening tests or definitive treatments for this infection in Japan. We report a case of a 21-day-old Japanese boy with congenital CMV infection. He was referred to our hospital for treatment of congenital bilateral deafness. Brain magnetic resonance imagingmrirevealed cortical dysplasia of the temporal poles, enlarged ventricles, and areas of abnormal intensity in the white matter. He was given a diagnosis of congenital CMV infection based on the detection of CMV DNA in his urine and the umbilical cord. After the administration of valganciclovir, no CMV DNA was detected in his serum, and brain MRI and electroencephalogram findings, motor development, and deafness improved. Further investigation is needed to establish a screening test and treatment for congenital CMV infection in Japan. No To Hattatsu 2012 ;44 :

BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI

BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI 20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old

More information

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate 37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5

More information

_02三浦.indd

_02三浦.indd 36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut

More information

indd

indd 18 61 1 2011 症例報告 2010 5 13 2010 12 20 A Case of Varicella with Severe Back Pain in a Patient with Systemic Lupus Erythematosus RIE SAITO, KIORI YANO, FUMIKO KATSUSHIMA, HARUYO IWADATE, HIROKO KOBAYASHI,

More information

小児感染免疫第25巻第2号

小児感染免疫第25巻第2号 Vol. 25No. 2145 1,2 1 1 1 1 2 2 2 TFLX 9 TFLX 450 mg16.6 mgkg TFLX 30 kg TFLX 2009 10 TFLX 1 1 2 3,4 TFLX 9 22 6 18 19 TFLX 450 mg150 mg 1 1 1 3 16.6 mgkg 20 20 0 21 3 135.0 cm0.1 S.D. 27.0 kg0.8 S.D.

More information

sick contact1l

sick contact1l Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5

More information

untitled

untitled - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -

More information

日赤 No.35☆/7.河相

日赤 No.35☆/7.河相 2 64 2 Mucosa-Associated Lymphoid TissueMALT T γ- 1 Key words T 1 2 64 47 54 60 MALT 63 T MALT 6062-8 63 1 T MALT 63 CHOP 2 35 28 30 28 75 μg 200 mg 20 mg 200 mg 400 mg/80 mg 2 35 mg 1 2 150 mg 200 mg

More information

小児感染免疫第29巻第2号

小児感染免疫第29巻第2号 小児感染免疫 Vol. 29 No. 2 153 症例報告 1 1 1 1 1 1 11 2 15C 14 17 細菌性髄膜炎は, 肺炎球菌, インフルエンザ菌 b 型ワクチン導入により減少傾向であるが, 現在でも予後不良な疾患である. 先天性内耳奇形では, 細菌性髄膜炎を発症することがあることが知られているが 1,2), 細菌性髄膜炎を発症したワクチン未接種の先天性内耳奇形の 1 例を経験したため報告する.

More information

九州支部卒後研修会症例

九州支部卒後研修会症例 血液検査研修会 ( 第 25 回 ) 検査の異常から探る! 造血器腫瘍へのアプローチ 症例提示 症例 1~8 - 症例発表者 - 症例 1 藤崎恵熊本医療センター 症例 2 荒木敏造浜の町病院 症例 3 古城剛鹿児島大学病院 症例 4 佐々木高太郎都城健康サービスセンター 症例 5 矢田佳愛 大分県立病院 症例 6 下田博臣 健康保険諫早総合病院 症例 7 堤陽子 佐賀県医療センター好生館 症例 8

More information

Sample2 g/dl Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl

Sample2 g/dl Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl ( ) Sample2 g/dl 10 9 8 7 6 Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl 117 5.92 0.09 1.6 118 5.92 0.10 1.6 7 5.77 0.14 2.4 118 8.28 0.15 1.8 118 8.28 0.15 1.8 7 7.26 0.46 6.4 119 119 6.84 7.10 0.11 0.11

More information

untitled

untitled Metabolic syndrome,,,, 81 81 , 17 17 2 Lung Ca non small cell carcinoma / / food( food( ) drug( drug( ) 100mg 750mg WBC 5510/ l RBC 483 / l Hb 10.3g/dl, Ht 42.0% Plt 19.0 / l TP 8.1g/dl Alb 4.6g/dl Glb

More information

indd

indd 60 4 2010 197 症例報告 1 1 1 2 2 2 2 3 4 1 2 3 4 2010 7 27 2010 9 24 Case of a Young Adult Male Complicated with Ischemic Colitis EMI OGATA 1, TAKERU WAKATSUKI 1, HIROAKI SAKAMOTO 1, NATSUMI SAKAMOTO 2, OSAMU

More information

400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC

400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17

More information

/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg

/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg 17 2005/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 32 5/8 36.1 :90 /:114/64 mmhg 166.2 cm64.3 kg 3.9 g/dl 1.6 g/dl 382 mg/dl 408 mg/dl

More information

医学紀要04-瀬戸上.indd

医学紀要04-瀬戸上.indd Med. Bull. Fukuoka Univ.39 3/4257 261 2012 A Case of a Neonate with Severe Congenital Toxoplasmosis Takashi SETOUE 1, 2 Eiji OHTA 1, 2 Terufumi GOUSHI 3 1, 2 Shinichi HIROSE 1 Division of Neonatology,

More information

1996 papilloma virus 2001 Bowen AIHA PSL1mg/kg BMA PRCA parvovirus B19 PVB19 DNA PCR PV IgM 4 PVB19 PRCA MAP PVB19 DNA DNA PR

1996 papilloma virus 2001 Bowen AIHA PSL1mg/kg BMA PRCA parvovirus B19 PVB19 DNA PCR PV IgM 4 PVB19 PRCA MAP PVB19 DNA DNA PR 1996 papilloma virus 2001 Bowen2002 12 2003 2 2002 9 10 AIHA PSL1mg/kg BMAPRCA parvovirus B19 PVB19 DNA PCR PV IgM 4PVB19 PRCA MAPPVB19DNA DNA PRCA IVIG;20 50g/ IVIG PVB19AIHA steroid 15 20mg/day 2003

More information

小児感染免疫第27巻第4号

小児感染免疫第27巻第4号 2015 小児感染免疫 Vol. 27 No. 4 285 10 1 4 1,2 3 4 10 cat scratch diseasecsd CSD CSD cat scratch diseasecsd Bartonella henselae CSD 30 46 1 CSD B. henselae 21.4 2 7 CSD CSD 10 7 9 9 26 37 40 9 30 CDTR PI 10

More information

72 20 Ope / class Alb g/ cm 47.9kg : /min 112/60m

72 20 Ope / class Alb g/ cm 47.9kg : /min 112/60m 72 20Ope 68 69 2006 4 50 20 / 52 2006 4 1 2006 4 4 24 class 699.4 5 2 5 23 6 6 15 6 19 6 16 Alb2.03+ 7.5g/ 6 21 153.5cm 47.9kg : 36.7 89/min112/60mmHg (-) (-)S1 S2 S3(-) S4(-) - - 6 15 (+) TP4.9g/dl Alb2.0g/

More information

顔面神経麻痺を来したMPO―ANCA 陽性の中耳炎2症例

顔面神経麻痺を来したMPO―ANCA 陽性の中耳炎2症例 11367 : MPOANCA MPO ANCA MPOANCA 134EU MPO ANCA 67EU MPOANCA ANCA : MPOANCAANCA antineutrophil cytoplasmic antibody ; ANCA Davies IgG ANCA PR3proteinase3ANCA MPOmyeloperoxidaseANCA Wegener PR3ANCA MPO

More information

E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian

More information

28 1 1a 1b 2 MRI T2 3 CT C3 N95 N95 6ml 90

28 1 1a 1b 2 MRI T2 3 CT C3 N95 N95 6ml 90 2015 28 1 89 93 CT C3 Tb PCR XP WBC 7 600/mm 3 CRP 4 08mg/dl MRI MRI CT MRI WBC 9 700/mm 3 CRP 6 09mg/dl CT C3 C2 C7 low density area CT 89 28 1 1a 1b 2 MRI T2 3 CT C3 N95 N95 6ml 90 28 1 4 CT C2 C7 low

More information

M1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1

More information

SARS HIV/AIDS n = 672; % 5% 2% 8% 16% 43% 20%

SARS HIV/AIDS n = 672; % 5% 2% 8% 16% 43% 20% SARS HIV/AIDS n = 672; 20074 20108 6% 5% 2% 8% 16% 43% 20% 1999 2008 HIV/AIDS B A 0% 50% 100% 1049 552 17 186 867 431 739 3847 332 7556 102 2420 3648 449 802 2709 31774 1286 13651 1611 207 95 8 162 667

More information

(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..

(1) ) ) (2) (3) (4) (5) (1) (2) b (3).. ... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32

More information

125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10

125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10 . (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1

More information

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio 7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine

More information

112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6 7 B 2 NTT 2012 6

112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6 7 B 2 NTT 2012 6 Apr. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 111 53 8 8 1. Ph-ALL Liposomal amphotericin B 1 2. CBT MCFG L-AMBAML 2 112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6

More information

Title 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL Right Posted at the Inst

Title 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL   Right Posted at the Inst Title 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL http://hdl.handle.net/10130/526 Right Posted at the Institutional Resources for Unique Colle Available from

More information

1) Urlne analysls 7)Serologlcal exam. 1 1)ECG W.N.L. sugar 0% CRP (-) urobillnogen N(+) RA (+) 12)Renal function albumin 3(+) ASLO (-) PSP test 15' 40

1) Urlne analysls 7)Serologlcal exam. 1 1)ECG W.N.L. sugar 0% CRP (-) urobillnogen N(+) RA (+) 12)Renal function albumin 3(+) ASLO (-) PSP test 15' 40 A case of membranoproliferative glomerulonephritis accompanied with hyper IgM immunodeficiency Kenichiro SHIGEMOTO, Koji WADA, Naoki HAMAGUCHI, Akira HIRABAYASHI, Shunji TOI, Koji USUI, Michiko ARITA,

More information

日本呼吸器学会雑誌第47巻第6号

日本呼吸器学会雑誌第47巻第6号 Fig.1 A,ChestX-rayfilm demonstratingatumorshadow intherightlowerlungfield.b,chestct scan demonstratingtherightmiddlelobemass,measuring9.0 7.3cm.C,AbdominalCT scanshowingfree airintheabdominalcavityanddirtyfatsignaroundthesigmoidcolontumor.

More information

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin

More information

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii

More information

2 章 +αの 情 報 に 着 目 する! 1 血 球 算 定 検 査 結 果 2 生 化 学 検 査 結 果 手 がかりに 乏 しいのも+α 1 症 例 をみてみよう! 1 60 吉 見 祐 輔 1 2 11percutaneous coronary intervention PCI104 38.

2 章 +αの 情 報 に 着 目 する! 1 血 球 算 定 検 査 結 果 2 生 化 学 検 査 結 果 手 がかりに 乏 しいのも+α 1 症 例 をみてみよう! 1 60 吉 見 祐 輔 1 2 11percutaneous coronary intervention PCI104 38. 2 章 +αの 情 報 に 着 目 する! 1 血 球 算 定 検 査 結 果 2 生 化 学 検 査 結 果 手 がかりに 乏 しいのも+α 1 症 例 をみてみよう! 1 60 吉 見 祐 輔 1 2 11percutaneous coronary intervention PCI104 38.1 130 75mmHg 83 16 SpO 297 1 3 WBCL RBC10 4 L Hb g

More information

日本呼吸器学会雑誌第44巻第6号

日本呼吸器学会雑誌第44巻第6号 Aspergillus β Table1 Laboratoryfindingsonadmission Hematology WB Seg Band Lymph Eos Baso RB Hb Hct Plt Biochemistry AST ALT LD ALP γ-gtp K 17,700 /mm 3 70.0 % 7.0 % 17.0 % 2.0 % 1.0 % 337 10 4 /mm 3 11.5g/dl

More information

日本職業・災害医学会会誌第51巻第5号

日本職業・災害医学会会誌第51巻第5号 太田ら 同時多発性高血圧性脳葉出血の 1 手術例 図 1 搬入時 CT 上段 単純 CT 下段 造影 CT 図 2 術後の脳血管撮影検査では明らかな出血源は認めない 379 Reprint request: MULTIPLE SIMULTANEOUS HYPERTENSIVE LOBAR HEMORRHAGE Hirotsugu OHTA M.D. 1) and Akira YOKOTA M.D.

More information

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S. Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S. Table 1. Clinical summary of acute uncomplicated cystitis patients treated with 7432-S UTI : Criteria by the

More information

日本呼吸器学会雑誌第44巻第10号

日本呼吸器学会雑誌第44巻第10号 β Table1 Laboratoryfindingsonthefirstvisit Hematology WBC Neut. Lyn. Mon. Eos. Bas. RBC Hb Ht Plate 5,650 /μl 79.2 % 14.9 % 3.9 % 1.8 % 0.2 % 418 10 4 /μl 12.5g/dl 38.4 % 21.2 10 4 /μl Serology CRP IgG

More information

Key words: pure red cell anemia, allogeneic bone marrow transplantation.

Key words: pure red cell anemia, allogeneic bone marrow transplantation. Complete Recovery of Hemopoiesis Following Bone Marrow Transplantation in a Patient with Unresponsive Congenital Pure Red Cell Anemia Masami SHIMADA, Hideo MUGISHIMA, Mitsuhiko HARA, Masahiro MISAWA, Hideo

More information

Rinku General Medical Center

Rinku General Medical Center Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines

More information

SBP hospitalist network.key

SBP hospitalist network.key 1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous

More information

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration

More information

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin

More information

無水エタノールによる硬化療法および鼻粘膜癒着処置を施行したオスラー病による難治性鼻出血の1例

無水エタノールによる硬化療法および鼻粘膜癒着処置を施行したオスラー病による難治性鼻出血の1例 119 874 2016 : 0 1cc : : : : : :WBC3 640/μl RBC 247 10 /μl PLT 22 9 10 /μl Hb 7 9g/dl PT APTT : : : 1ml 30G absolute ethanol Et 0 1 0 2ml 2mm 119 875 1 000mg/day Et 0 3ml Al Deen endoglin ALK1 1 3 a b

More information

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin

More information

1) Delbet P: Retrocissement du choledoque. Cholecysto-duodenostomie. Bull Mem Soc Nat Chir 50: 1144-1146, 1924 2) Wiesner RH, LaRusso NF: Clinicopathologic Features of the Syndrome of Primary Sclerosing

More information

untitled

untitled 1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,

More information

2 W.T T.S. 70 2 1 238 WBC7400/µl, RBC 386 10 4 /µl, Hb 11.6 g/dl, Ht 36.2%, PLT 25 10 4 /µl AST 19 IU/l, ALT 11 IU/l, LDH 182 IU/l, BUN 15 mg/dl, Cr 0.54 mg/dl, CRP6.83 mg/dl, RF 353.9IU/ml, CCP 28.0IU/ml

More information

表 1 WBC 7,700/μ C3 142 mg/d 1.014 Eos 2.3 C4 41 mg/d ph 7.0 Hb 12 g/d IgG 984 mg/d 2+ TP 6.9 g/d IgA 323 mg/d 3+ Alb 3.7 g/d IgM 110 mg/d 1+ BUN 19.2

表 1 WBC 7,700/μ C3 142 mg/d 1.014 Eos 2.3 C4 41 mg/d ph 7.0 Hb 12 g/d IgG 984 mg/d 2+ TP 6.9 g/d IgA 323 mg/d 3+ Alb 3.7 g/d IgM 110 mg/d 1+ BUN 19.2 症 例 報 告 1 1 1 2 1 1 1 3 24 11 5 25 3 14 要 14 5 Cr 1.7 mg/d egfr 45.0 m /min/1.73 m 2 β2mg 45,400 μg/ IgA 序 Mycoplasma pneumoniae 症 旨 言 例 症 例 :14 主 訴 : 1 815-8555 3-1-1 2 3 家 族 歴 : 既 往 歴 :3 2 生 活 歴 : 現

More information

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案) VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.

More information

血糖高いのは朝食後のため検査項目 下限値上限値 単位名称 9 月 3 日 9 月 6 日 9 月 15 日 9 月 18 日 9 月 21 日 9 月 24 日 9 月 28 日 10 月 1 日 10 月 3 日 10 月 5 日 10 月 9 日 10 月 12 日 10 月 15 日 10 月

血糖高いのは朝食後のため検査項目 下限値上限値 単位名称 9 月 3 日 9 月 6 日 9 月 15 日 9 月 18 日 9 月 21 日 9 月 24 日 9 月 28 日 10 月 1 日 10 月 3 日 10 月 5 日 10 月 9 日 10 月 12 日 10 月 15 日 10 月 検査項目 下限値上限値 単位名称 7 月 9 日 7 月 10 日 7 月 11 日 7 月 12 日 7 月 13 日 7 月 17 日 7 月 20 日 7 月 23 日 7 月 25 日 7 月 27 日 7 月 30 日 8 月 3 日 8 月 6 日 8 月 8 日 8 月 10 日 8 月 12 日 8 月 15 日 8 月 17 日 8 月 20 日 8 月 22 日 8 月 24 日

More information

1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61

1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61 1 2 2 ANCApouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - '03 2 3 31 UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, 3+ 4 14 156.0 cm 61.5 kg 36.9 158/92 mmhg 90 1. ANCA 2. 3. IgG4 deposit

More information

387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )

387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )

More information

2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,

2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ , 24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998

More information

_06.indd

_06.indd 30, 35-39, 2010 0.15% 1 C 40 20 1 cm 5 mm WBC 9,400, RBC 259 10 4, Hb 8.5 g/dl, Ht 25.5%, Plt 29 10 4, BUN 116 mg/dl, Cr 7.9 mg/dl, 125 mg/dl, HbA1c 4.3%, ft3 1.97 pg/ml, ft4 1.05 ng/dl, TSH 1.09 μiu/ml,

More information

東洋医学雑誌

東洋医学雑誌 Vol.67 No.3 296-301, 2016 Keizo TOKUMO Department of Obstetrics and Gynecology, Chugoku Central Hospital of the Mutual aid Association of Public School Teachers, 148-13 Ohazaueiwanari, Miyuki-cho, Fukuyama,

More information

日本職業・災害医学会会誌第54巻第6号

日本職業・災害医学会会誌第54巻第6号 Reprint request: A CASE OF PRESENTED VARIOUS FUNCTIONAL DISTURBANCES AFTER AN INJURY Taketoshi NOGAKI, Nobusuke HOUCHI, Tomoko SUGIUCHI, Naohiko WATANABE and Hiroyuki ZUSHO Department of Otolaryngology,

More information

CT 5 HE PSA PAP 6 1 1

CT 5 HE PSA PAP 6 1 1 45 2140 145 2006 70 PSA 33.32 ng/ml Gleason score 5+4=9 MRIcT4N1M1b 4 PSA 1 4 PSAPAP 1 11.9 1 1.9-70 PSA33.32 ng/ml Gleason score 5+4=9 2006 5 10 570-8540 5-55 1 MRI2 3 ct4n1m1b 4 PSA NSAIDs 11 4 37.4

More information

3 m/sec 8.35 39.06 3.22 2.15 13.72 52.78 15.00 2.12 2.69 12.62 27.62 3 m/ 772 79 68 263 410 1,182 3 m/sec 3.87 0.63 8.00 3.12 1.38 12.50 12.50 2.00 2.50 1.00 5.50 5.50 m/ 105 122 20 247 247 3 m/sec 0.23

More information

慈大呼吸器_25-1_02T_CS5.indd

慈大呼吸器_25-1_02T_CS5.indd ISSN 0919-6870. Jikei Journal of Chest Diseases Jikei University Chest Diseases Research Association 82 1 1 1 1 1 1 1 1 2 1 2 74 2010 2 2011 8 12 2012 1 17 1 20 1 28 CT 5 / 50 2011 8 2 / 1200 mg/2x 40

More information

サイトメガロウイルスの母子感染

サイトメガロウイルスの母子感染 サイトメガロウイルスの母子感染 宮崎大学産婦人科准教授 金子政時 はじめに胎内サイトメガロウイルス (CMV) 感染症は 乳幼児に神経学的後遺症を起こす可能性のある周産期ウイルス感染症である しかし 母体にCMV 感染が成立したとしても それが胎盤を通して胎児に感染するかどうか さらに 胎児感染してもどれくらい児へ影響を及ぼすかどうかは それぞれ別の問題となってくる よって 診断においては 児の予後を予測できるような診断法が望まれる

More information

untitled

untitled ---------- - 1 - ----- 1 Q1 5 Q2 5 Q3 5 Q4 6 Q5 6 Q6 7 Q7 7 Q8 7 Q9 8 Q10 : 8 10 Q1 10 Q2 11 Q3 11 12 Q4 12 Q5 HBs HBc _12 Q6 HBe 12 Q7 13 Q8 NAT 15 Q9 15 Q10 15 Q11 HBs 16 Q12 HBV DNA 16 Q13 17-2 - Q14

More information

VOL.42 S-1

VOL.42 S-1 CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical

More information

CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table

More information

21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty

More information

21 70.9 22 62.9 22 90 80 60 40 23 58 17 42 31 77.5 9 22.5 1 n 40 40 0 2 2 5.0 50 0 3 3 7.5 60 3 12 15 37.5 70 12 5 17 42.5 80 1 1 2 5.0 90 1 0 1 2.5 4

21 70.9 22 62.9 22 90 80 60 40 23 58 17 42 31 77.5 9 22.5 1 n 40 40 0 2 2 5.0 50 0 3 3 7.5 60 3 12 15 37.5 70 12 5 17 42.5 80 1 1 2 5.0 90 1 0 1 2.5 4 462015 Nagoya community school for health Think health scientifically : the life style and the health condition of seminar participants Hisae USAMI 21 36 67 1/3 21 21 21 1 23 6 68.2 91 43 70 42.56037.5

More information

Osamu NEMOTO, M.D. Clinical and Bacteriological Research of Sucrose/ Povidone-Iodine Ointment (U-PASTA kowa) for Pressure Sores and Skin Ulcers Osamu Nemoto Department of Dermatology,Tonan Hosptal

More information

*1 *2 *1 JIS A X TEM 950 TEM JIS Development and Research of the Equipment for Conversion to Harmless Substances and Recycle of Asbe

*1 *2 *1 JIS A X TEM 950 TEM JIS Development and Research of the Equipment for Conversion to Harmless Substances and Recycle of Asbe *1 *2 *1 JIS A 14812008X TEM 950 TEM 1 2 3 4 JIS Development and Research of the Equipment for Conversion to Harmless Substances and Recycle of Asbestos with Superheated Steam Part 3 An evaluation with

More information

1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です

1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です 8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%

More information

TCI TCI TRT TRT TRT EQS TRT TRT MMPI TRT II

TCI TCI TRT TRT TRT EQS TRT TRT MMPI TRT II Audiology Japan Vol. 50, No. 5 2007 ASSR NICU ABR ASSR I TCI TCI TRT TRT TRT EQS TRT TRT MMPI TRT II 3D FLAIR Lipo PGE1 Hearing Handicap Inventory for Elderly Screening version III A3243G trnaleu UUR 60dB

More information

高脂血症の検査

高脂血症の検査 35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH

More information

Clinical Observation and Etiological Aspect on the Thrombocytopenic Purpura after Rubella Toyoji SODA, Masashi KAWANO, Toshihiko KATO*, and Takeshi SH

Clinical Observation and Etiological Aspect on the Thrombocytopenic Purpura after Rubella Toyoji SODA, Masashi KAWANO, Toshihiko KATO*, and Takeshi SH Clinical Observation and Etiological Aspect on the Thrombocytopenic Purpura after Rubella Toyoji SODA, Masashi KAWANO, Toshihiko KATO*, and Takeshi SHIGEMATSU**, Rubella is an acute viral infectious disease

More information

24) Bergeron M.G., Menard C. et al: Rapid Detection 19) Aber R. C., Allen N., Howell J. T. et al.: Nosocomial Transmission of Group B Streptococci, Pediatrics, 58(3), 346-359, 1976. 20) Baker C.J., Barrett

More information

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3- Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,

More information

緩和医療13巻1号 pp

緩和医療13巻1号 pp Palliative Care Research 2015; 10(3): 00 00 Palliat Care Res 2018; 13(1): 109 13 1 2 3 患者は 68 歳男性で, 左甲状腺腫瘍未分化転化の診断でレンバチニブを内服中, 左鎖骨周囲の腫脹, 疼痛がありトラマドールを内服開始した.2 日後から下痢, 発汗, 見当識障害, ミオクローヌスなどが認められたためセロトニン症候群と診断された.

More information

- 9 91, (2006)

- 9 91, (2006) Case study level Ma Management of testicular cancer - 9 91, 10 0.7 2.4 (2006) 20 30 20 20-40 AFP -hcg -hcg AFP TNM T ptx pt0 ptis pt1 / pt2 / pt3 / pt4 / N NX N0 N1 2cm 1 2cm N2 2cm 5cm 1 5cm N3 5cm TNM

More information

Clinical Study of Effect of Intrathecal Use of Alpha-tocopherol on Chronic Vasospasm Hirotoshi Sano, Motoi Shoda, Youko Kato, Kazuhiro Katada, Youichi

Clinical Study of Effect of Intrathecal Use of Alpha-tocopherol on Chronic Vasospasm Hirotoshi Sano, Motoi Shoda, Youko Kato, Kazuhiro Katada, Youichi Clinical Study of Effect of Intrathecal Use of Alpha-tocopherol on Chronic Vasospasm Hirotoshi Sano, Motoi Shoda, Youko Kato, Kazuhiro Katada, Youichi Shinomiya and Tetsuo Kanno Department of Neurosurgery,

More information

小児感染免疫第27巻第4号

小児感染免疫第27巻第4号 364 2015 C 1 2 3 4 5 6 7 8 urinary tract infection UTI 2 1 UTI 1 3 5 2,3 4 1 UTI Escherichia coli E. coli 80 5 Enterococcus 1 UTI 83 78 53 98 5 WBCs HPF 73 81 81 83 or 93 72 ororor 99.8 70 4 Key words

More information

デスフルラン

デスフルラン デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.

More information

! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The

More information

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b) 2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)

More information

Gifu University Hospital Cancer Center 1 2 Gifu University Hospital Cancer Center Gifu University Hospital Cancer Center 3 4 Gifu University Hospital Cancer Center Gifu University Hospital Cancer Center

More information

日本呼吸器学会雑誌第48巻第6号

日本呼吸器学会雑誌第48巻第6号 Fig.1 Cutaneousfindingsandpathologicalfindingsofatransbronchiallungbiopsy(TBLB)andlichenifiedeczemaoftherightforearm.Thepatienthadlichenifiedeczemaonhisextremitiesandbodytrunk (1a:rightforearm,1b:leftthigh).Therewasinfiltrationoftheinflammatorylymphocytes,edemaandabrasioninthetype2alveolarepithelium

More information

, PDD ASD p.,.,..,..,.,..,.,..,.,.,.,, 146

, PDD ASD p.,.,..,..,.,..,.,..,.,.,.,, 146 Study on the System of the Chinese Autistic in Japan Xiaotong Ro abstract This study note is mainly introduced the research of China s autistic child treatment in Japan. There is not very much research

More information

Fig. 1 Chemical structure of DL-8280

Fig. 1 Chemical structure of DL-8280 Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.

More information

日本呼吸器学会雑誌第44巻第1号

日本呼吸器学会雑誌第44巻第1号 β β l β β Table1 Laboratorydataonadmission Hematology WBC 9,910/μl neut 72.4% lym 20.2% eos 0.9% mon 6.1% baso 0.4% RBC 491 10 4 /μl Hb 16.8g/dl Ht 48.3% PLT 29.8 10 4 /μl ESR 3mm/hr Biochemistry TP Alb

More information

Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood

Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba

More information

JSACHD_Vol4_No2_Dec2015.book

JSACHD_Vol4_No2_Dec2015.book 4 2 30 35 (2015 ) cyanotic congenital heart disease, compensated erythrocytosis, iron replacement therapy ( 1) Hb = 57.5 (0.444 x ) 1) 1 2 30 (2015 12 ) SpO2 < 75% 2 (Ht) 2) Ht 3) QOL 4) MCV MCH TIBC Ht

More information

エンジョイ北スポーツ

エンジョイ北スポーツ 2672080127 3 1 2 3 2 3 4 4 5 5 5 7 8 4 5 6 7 8 1411 55/14,817 /259/655/13,903 2 80127 http://www.kita-city-taikyo.or.jp TOKYO TOKYO 80127 http://www.kita-city-taikyo.or.jp 3 4 80127 http://www.kita-city-taikyo.or.jp

More information

東洋医学雑誌

東洋医学雑誌 Vol.61 No.7 924-929, 2010 a b c d Naoki OKADA ad Masaru NATSUAKI b Takashi NISHIMOTO ac Nishimoto Clinic, 2-8-31 Koshienguchi, Nishinomiya, Hyogo 663-8113, Japan Department of Dermatology, Hyogo College

More information

001-029_”÷’X

001-029_”÷’X 54 2012 1 29 Kimori Daisuke Kamijo Takashi Takahashi Akira 1993 19951997 2001 10 1993 1999 1992 54 2012 1993 20 LDH BUNCRE UA CPK GOT CPK LDH UA CPK LDH UA CPK 1989 2001 2000 1989 1995 2003 2005 1989 54

More information

....

.... 2030 2 Vol. 22 No. 32000 1/2 EE F FAF 60E 1970 40 25FIP 1995 503cx 60 10M5 Vol. 22 No. 32000 3 carpal tunnel syndrome entrapment neuropathy cm 4 Vol. 22 No. 32000 5 Vol. 22 No. 32000 10 2- microglobulin

More information

Microsoft PowerPoint - 当日H3001標準化報告会用hiramitu.pptx

Microsoft PowerPoint - 当日H3001標準化報告会用hiramitu.pptx 平成 29 年度社団法人岐阜県臨床検査技師会精度管理報告会 標準化事業総括 平光幹彦 ( 岐阜市民病院 ) 精度管理調査結果報告 ( 標準化事業総括 ) 岐阜県総参加施設数 病院 診療所 51 検査センター 9 試薬メーカー 20 昨年より 病院 診療所で 4 施設増 日臨技の精度管理事業昭和 45 年から外部精度管理調査を開始全国参加施設 3800 施設以上現在 742 施設認証 1 項目 29

More information

Key words: Neonate, Intestinal flora, Infection, Bifidobacterium

Key words: Neonate, Intestinal flora, Infection, Bifidobacterium Key words: Neonate, Intestinal flora, Infection, Bifidobacterium Table 1 Media of aerobic culture (37 Ž 24 hrs) Table 2 Media of anaerobic culture (37 Ž 48 hrs ) Table 3 Methods for analysis of fecal flora

More information

The clinical characteristics of Mycoplasma pneumoniae pneumonia in children younger than 6 years old Nobue Takeda1,2),Tomomichi Kurosaki1),Naruhiko Ishiwada2),Yoichi Kohno2) 1)Department of Pediatrics,Chiba

More information

...S.....\1_4.ai

...S.....\1_4.ai * ** *** **** ***** ** ** ** ** ** * ** *** **** ***** 19 () 19 16 15:00 17:00 17:00 18:00 10 ABR 105dB : 40dB SPL:60dB(SPL) 17 ABR 100dB ( ):103dB(HL) ( ):104dB(HL) 50dB(SPL) 66 20 14 100) 100899810 4091

More information

難聴児の療育

難聴児の療育 Audiology Japan 52, 139 151, 2009 : 140 Audiology Japan 52, 2009 Downs MP 90dBSPL 2500 3500Hz Downs MP Joint Committee on Infant Hearing JCIH automated auditory brainstem response : AABR ABRotoacoustic

More information